Literature DB >> 27383589

Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.

Bridget A Matikainen-Ankney1, Nebojsa Kezunovic1, Roxana E Mesias1, Yuan Tian2, Frances M Williams1, George W Huntley3, Deanna L Benson3.   

Abstract

UNLABELLED: Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) can cause Parkinson's disease (PD), and the most common disease-associated mutation, G2019S, increases kinase activity. Because LRRK2 expression levels rise during synaptogenesis and are highest in dorsal striatal spiny projection neurons (SPNs), we tested the hypothesis that the LRRK2-G2019S mutation would alter development of excitatory synaptic networks in dorsal striatum. To circumvent experimental confounds associated with LRRK2 overexpression, we used mice expressing LRRK2-G2019S or D2017A (kinase-dead) knockin mutations. In whole-cell recordings, G2019S SPNs exhibited a fourfold increase in sEPSC frequency compared with wild-type SPNs in postnatal day 21 mice. Such heightened neural activity was increased similarly in direct- and indirect-pathway SPNs, and action potential-dependent activity was particularly elevated. Excitatory synaptic activity in D2017A SPNs was similar to wild type, indicating a selective effect of G2019S. Acute exposure to LRRK2 kinase inhibitors normalized activity, supporting that excessive neural activity in G2019S SPNs is mediated directly and is kinase dependent. Although dendritic arborization and densities of excitatory presynaptic terminals and postsynaptic dendritic spines in G2019S SPNs were similar to wild type, G2019S SPNs displayed larger spines that were matched functionally by a shift toward larger postsynaptic response amplitudes. Acutely isolating striatum from overlying neocortex normalized sEPSC frequency in G2019S mutants, supporting that abnormal corticostriatal activity is involved. These findings indicate that the G2019S mutation imparts a gain-of-abnormal function to SPN activity and morphology during a stage of development when activity can permanently modify circuit structure and function. SIGNIFICANCE STATEMENT: Mutations in the kinase domain of leucine-rich repeat kinase 2 (LRRK2) follow Parkinson's disease (PD) heritability. How such mutations affect brain function is poorly understood. LRRK2 expression levels rise after birth at a time when synapses are forming and are highest in dorsal striatum, suggesting that LRRK2 regulates development of striatal circuits. During a period of postnatal development when activity plays a large role in permanently shaping neural circuits, our data show how the most common PD-causing LRRK2 mutation dramatically alters excitatory synaptic activity and the shape of postsynaptic structures in striatum. These findings provide new insight into early functional and structural aberrations in striatal connectivity that may predispose striatal circuitry to both motor and nonmotor dysfunction later in life.
Copyright © 2016 the authors 0270-6474/16/367129-14$15.00/0.

Entities:  

Keywords:  G2019S; LRRK2; activity; dorsal striatum; spine morphology; synapse

Mesh:

Substances:

Year:  2016        PMID: 27383589      PMCID: PMC4938860          DOI: 10.1523/JNEUROSCI.3314-15.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  108 in total

1.  LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis.

Authors:  Samer Matta; Kristof Van Kolen; Raquel da Cunha; Geert van den Bogaart; Wim Mandemakers; Katarzyna Miskiewicz; Pieter-Jan De Bock; Vanessa A Morais; Sven Vilain; Dominik Haddad; Lore Delbroek; Jef Swerts; Lucía Chávez-Gutiérrez; Giovanni Esposito; Guy Daneels; Eric Karran; Matthew Holt; Kris Gevaert; Diederik W Moechars; Bart De Strooper; Patrik Verstreken
Journal:  Neuron       Date:  2012-09-20       Impact factor: 17.173

2.  Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.

Authors:  Rick C Helmich; Avner Thaler; Bart F L van Nuenen; Tanya Gurevich; Anat Mirelman; Karen S Marder; Susan Bressman; Avi Orr-Urtreger; Nir Giladi; Bastiaan R Bloem; Ivan Toni
Journal:  Neurology       Date:  2014-12-24       Impact factor: 9.910

3.  LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism.

Authors:  Amaia M Arranz; Lore Delbroek; Kristof Van Kolen; Marco R Guimarães; Wim Mandemakers; Guy Daneels; Samer Matta; Sara Calafate; Hamdy Shaban; Pieter Baatsen; Pieter-Jan De Bock; Kris Gevaert; Pieter Vanden Berghe; Patrik Verstreken; Bart De Strooper; Diederik Moechars
Journal:  J Cell Sci       Date:  2015-02-01       Impact factor: 5.285

4.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

5.  RAB-10 regulates glutamate receptor recycling in a cholesterol-dependent endocytosis pathway.

Authors:  Doreen R Glodowski; Carlos Chih-Hsiung Chen; Henry Schaefer; Barth D Grant; Christopher Rongo
Journal:  Mol Biol Cell       Date:  2007-08-29       Impact factor: 4.138

6.  Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.

Authors:  Avner Thaler; Anat Mirelman; Rick C Helmich; Bart F L van Nuenen; Keren Rosenberg-Katz; Tanya Gurevich; Avi Orr-Urtreger; Karen Marder; Susan Bressman; Bastiaan R Bloem; Nir Giladi; Talma Hendler
Journal:  Cortex       Date:  2013-01-07       Impact factor: 4.027

7.  Cholinergic interneurons mediate fast VGluT3-dependent glutamatergic transmission in the striatum.

Authors:  Michael J Higley; Aryn H Gittis; Ian A Oldenburg; Nina Balthasar; Rebecca P Seal; Robert H Edwards; Bradford B Lowell; Anatol C Kreitzer; Bernardo L Sabatini
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

8.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Authors:  Martin C Herzig; Carine Kolly; Elke Persohn; Diethilde Theil; Tatjana Schweizer; Thomas Hafner; Christine Stemmelen; Thomas J Troxler; Peter Schmid; Simone Danner; Christian R Schnell; Matthias Mueller; Bernd Kinzel; Armelle Grevot; Federico Bolognani; Martina Stirn; Rainer R Kuhn; Klemens Kaupmann; P Herman van der Putten; Giorgio Rovelli; Derya R Shimshek
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

9.  Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.

Authors:  Genta Ito; Tetta Fujimoto; Shogo Kamikawaji; Tomoki Kuwahara; Takeshi Iwatsubo
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

10.  The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.

Authors:  Eric S Sweet; Bernadette Saunier-Rebori; Zhenyu Yue; Robert D Blitzer
Journal:  J Neurosci       Date:  2015-08-12       Impact factor: 6.167

View more
  45 in total

Review 1.  Functional and behavioral consequences of Parkinson's disease-associated LRRK2-G2019S mutation.

Authors:  Deanna L Benson; Bridget A Matikainen-Ankney; Ayan Hussein; George W Huntley
Journal:  Biochem Soc Trans       Date:  2018-12-04       Impact factor: 5.407

Review 2.  Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Authors:  Yvette C Wong; Kelvin Luk; Kerry Purtell; Samuel Burke Nanni; A Jon Stoessl; Louis-Eric Trudeau; Zhenyu Yue; Dimitri Krainc; Wolfgang Oertel; Jose A Obeso; Laura A Volpicelli-Daley
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

3.  Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.

Authors:  Carissa D Winland; Nora Welsh; Alberto Sepulveda-Rodriguez; Stefano Vicini; Kathleen A Maguire-Zeiss
Journal:  Eur J Neurosci       Date:  2017-10-10       Impact factor: 3.386

Review 4.  Role of the endolysosomal system in Parkinson's disease.

Authors:  D J Vidyadhara; John E Lee; Sreeganga S Chandra
Journal:  J Neurochem       Date:  2019-07-31       Impact factor: 5.372

5.  LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks.

Authors:  Katharina A Schindlbeck; An Vo; Nha Nguyen; Chris C Tang; Martin Niethammer; Vijay Dhawan; Vicky Brandt; Rachel Saunders-Pullman; Susan B Bressman; David Eidelberg
Journal:  Cereb Cortex       Date:  2020-05-14       Impact factor: 5.357

6.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

7.  Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo.

Authors:  Qihui Wu; Muhammad A Shaikh; Emily S Meymand; Bin Zhang; Kelvin C Luk; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2020-10-06       Impact factor: 17.088

Review 8.  Are we listening to everything the PARK genes are telling us?

Authors:  Deanna L Benson; George W Huntley
Journal:  J Comp Neurol       Date:  2019-02-08       Impact factor: 3.215

9.  Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3-/- Mice, a Genetic Model of Parkinson's Disease.

Authors:  Luz M Suarez; Samuel Alberquilla; Jose R García-Montes; Rosario Moratalla
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

10.  The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.

Authors:  Kaela Kelly; Shijie Wang; Ravindra Boddu; Zhiyong Liu; Omar Moukha-Chafiq; Corinne Augelli-Szafran; Andrew B West
Journal:  Exp Neurol       Date:  2018-07-24       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.